Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11289917 | 0.82 | CYP2D6 (0.46) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7075474 | 0.80 | EIF4A1 (0.49) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL8553165 | 0.80 | CYP2D6 (0.46) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7221372 | 0.80 | CYP2D6 (0.46) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL8556340 | 0.77 | KCNH2 (0.45) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL1125455 | 0.74 | HDAC8 (0.49) | MAPTSMN1; SMN2LMNACNR1TRPM8 | |
| SCHEMBL8575500 | 0.74 | LMNA (0.49) | SMN1; SMN2LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15761208 | 0.73 | TAS2R14 (0.46) | MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL29699666 | 0.73 | TAS2R14 (0.46) | MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7219638 | 0.73 | CYP3A4 (0.45) | CYP3A4MAPTSMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716265-B2 | 4-quinolinemethanols as anti-malarial agents | JENRIN DISCOVERY, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716265-B2 | 4-quinolinemethanols as anti-malarial agents | JENRIN DISCOVERY, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120178717-A1 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | JENRIN DISCOVERY (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178717-A1 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | JENRIN DISCOVERY (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012068560-A2 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | JENRIN DISCOVERY (US) | 2012-05-24 | — | — | WO | disclosed |
| US-6664397-B1 | Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects | VERNALIS RESEARCH LIMITED (GB) | 2003-12-16 | — | — | US | disclosed |
| US-6197788-B1 | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders | VERNALIS RESEARCH LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| EP-0975345-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | Cerebrus Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999026627-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | CEREBRUS LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178717-A1 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | CYP51A1, SQLE, NQO2 | CYP3A4 20/4885MAPT 484/4885SMN1; SMN2 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.